http://www.pvct.com Provectus Pharmaceuticals News Channel en-us Copyright @ 2010 Provectus Pharmaceuticals Inc. All rights reserved. http://www.pvct.com/images/pvct_logo_rss.gif http://www.pvct.com 107 26 Tue, 27 Jul 2010 12:42:22 GMT Tue, 27 Jul 2010 12:40:21 +0000 Provectus has signed an agreement with Numoda Capital Innovations LLC (http://www.numodacapital.com) to license its TruPoints strategic partnering platform. http://www.pvct.com/pressrelease.html?article=20100727 http://www.pvct.com/pvctnews#0091/ Mon, 19 Jul 2010 19:37:31 +0000 An article on Ipilimumab appearing in Oncology NEWS International contains a sidebar on PV-10 for metastatic melanoma. http://www.pvct.com/inthenews.html?article=20100719&mode=0 http://www.pvct.com/pvctnews#0090/ Thu, 15 Jul 2010 14:46:23 +0000 Provectus reports on its first half 2010 clinical and corporate accomplishments, as well as its clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. http://www.pvct.com/pressrelease.html?article=20100715 http://www.pvct.com/pvctnews#0089/ Thu, 8 Jul 2010 12:59:33 +0000 A news brief appearing in HemOnc Today titled "Rose bengal active in metastatic melanoma" briefly summarizes positive results from the Phase 2 clinical trial of PV-10 for metastatic melanoma. http://www.hemonctoday.com/article.aspx?rid=66294 http://www.pvct.com/pvctnews#0088/ Wed, 7 Jul 2010 16:22:12 +0000 In an article titled "Promising Data on Ipilimumab and Other Investigational Melanoma Therapies", appearing in the Oncololgy Watch department of the July 2010 issue of Practical Dermatology, Jonathan Wolfe, MD discusses promising findings on potential new treatments for advanced melanoma, including PV-10. http://www.pvct.com/news/PracticalDermatology-0710.pdf http://www.pvct.com/pvctnews#0087/ Mon, 14 Jun 2010 14:29:02 +0000 Video of a presentation given by Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals, at the Southern California Investment Association Summer Conference on June 5, 2010 is available on the SCIA website. http://www.sciaconference.com/PublicCo/June2010/PVCT/Index.html http://www.pvct.com/pvctnews#0086/ Thu, 10 Jun 2010 16:30:02 +0000 Video of a presentation expanding on the PV-10 data presented in the poster session at ASCO 2010 given by Dr. Sanjiv Agarwala is available on the Provectus website. http://www.pvct.com/ASCO2010.html http://www.pvct.com/pvctnews#0085/ Mon, 7 Jun 2010 13:06:12 +0000 Provectus has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma at ASCO 2010. http://www.pvct.com/pressrelease.html?article=20100607 http://www.pvct.com/pvctnews#0084/ Fri, 21 May 2010 14:13:21 +0000 The Southern California Investment Association has announced that Provectus will be presenting at the SCIA Summer Conference. The SCIA Summer Conference will be held Saturday June 5, 2010 at the Hilton Hotel/Orange County Airport in Irvine, CA. http://www.marketwire.com/press-release/SCIA-Announces-Additional-Companies-TSX-NNN-1264582.htm http://www.pvct.com/pvctnews#0083/ Fri, 21 May 2010 12:13:12 +0000 Provectus has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR. http://www.pvct.com/pressrelease.html?article=20100521 http://www.pvct.com/pvctnews#0082/ Thu, 29 Apr 2010 12:53:15 +0000 Provectus announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. http://www.pvct.com/pressrelease.html?article=20100429 http://www.pvct.com/pvctnews#0081/ Thu, 1 Apr 2010 19:26:19 +0000 PV-10 for metastatic melanoma discussed in Molecular Oncology article. http://eorder.sheridan.com/3_0/display/index.php?flashprint=446 http://www.pvct.com/pvctnews#0080/ Wed, 24 Mar 2010 14:07:01 +0000 Provectus announces that Craig Dees, Ph.D., CEO, will appear at the CFA Society of Nevada. http://www.pvct.com/pressrelease.html?article=20100324 http://www.pvct.com/pvctnews#0079/ Thu, 18 Mar 2010 16:38:14 +0000 Provectus announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois. http://www.pvct.com/pressrelease.html?article=20100318 http://www.pvct.com/pvctnews#0078/ Mon, 15 Mar 2010 12:33:15 +0000 Provectus announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the "bystander effect" in treating metastatic melanoma. http://www.pvct.com/pressrelease.html?article=20100315 http://www.pvct.com/pvctnews#0077/ Fri, 12 Mar 2010 13:54:31 +0000 Provectus announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. http://www.pvct.com/pressrelease.html?article=20100312 http://www.pvct.com/pvctnews#0076/ Tue, 9 Mar 2010 16:45:53 +0000 Provectus announced today that it has signed agreements with various institutional and accredited investors for the private placement of an aggregate of approximately 7.1 million shares of its convertible preferred stock and warrants to purchase approximately 3.55 million shares of its common stock at an exercise price of $1.00 per share. http://www.pvct.com/pressrelease.html?article=20100309 http://www.pvct.com/pvctnews#0075/ Mon, 8 Mar 2010 14:49:33 +0000 Dr. Sanjiv Agarwala will present an update on the ongoing Phase 2 trial of PV-10 for metastatic melanoma at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, in New York City. http://www.pvct.com/pressrelease.html?article=20100308 http://www.pvct.com/pvctnews#0074/ Tue, 2 Mar 2010 14:54:13 +0000 Mentor Capital, Inc. recently added Provectus to their Cancer Immunotherapy Index. http://www.pvct.com/news/20100302.html http://www.pvct.com/pvctnews#0073/ Tue, 9 Feb 2010 14:11:31 +0000 Provectus announces publication in peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010). http://www.pvct.com/pressrelease.html?article=20100209 http://www.pvct.com/pvctnews#0072/ Thu, 7 Jan 2010 15:15:21 +0000 Provectus reports on its 2009 clinical and corporate accomplishments, as well as 2010 clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. http://www.pvct.com/pressrelease.html?article=20100107 http://www.pvct.com/pvctnews#0071/ Mon, 14 Dec 2009 15:14:11 +0000 An article titled "A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series" has been made available for purchase ahead of print. http://journals.lww.com/melanomaresearch/toc/publishahead http://www.pvct.com/pvctnews#0070/ Tue, 1 Dec 2009 13:19:41 +0000 Provectus announced preliminary data for the company's PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis. http://www.pvct.com/pressrelease.html?article=20091201 http://www.pvct.com/pvctnews#0069/ Mon, 23 Nov 2009 15:19:31 +0000 Provectus announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data. http://www.pvct.com/pressrelease.html?article=20091123 http://www.pvct.com/pvctnews#0068/ Tue, 17 Nov 2009 16:27:37 +0000 Professor John F. Thompson, MD, Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany. http://www.pvct.com/pressrelease.html?article=20091117 http://www.pvct.com/pvctnews#0067/ Tue, 3 Nov 2009 18:51:32 +0000 Provectus recently updated its Business Presentation and Corporate Fact Sheet. http://www.pvct.com/presskit.html http://www.pvct.com/pvctnews#0066/ Tue, 3 Nov 2009 18:50:03 +0000 An interview with Provectus CFO and COO Peter Culpepper appeared in The Wall Street Transcript November 2, 2009. http://www.pvct.com/news/TWST_Provectus_2009-11-02.pdf http://www.pvct.com/pvctnews#0065/ Wed, 14 Oct 2009 14:00:27 +0000 Provectus has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. http://www.pvct.com/pressrelease.html?article=20091014 http://www.pvct.com/pvctnews#0064/ Tue, 13 Oct 2009 13:23:17 +0000 Provectus has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. http://www.pvct.com/pressrelease.html?article=20091013 http://www.pvct.com/pvctnews#0063/ Thu, 1 Oct 2009 11:32:12 +0000 Provectus has initiated a Phase 1 study of PV-10 for liver cancer. http://www.pvct.com/pressrelease.html?article=20091001 http://www.pvct.com/pvctnews#0062/ Mon, 21 Sep 2009 14:41:02 +0000 Provectus has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. http://www.pvct.com/pressrelease.html?article=20090921 http://www.pvct.com/pvctnews#0061/ Wed, 16 Sep 2009 17:01:17 +0000 Provectus will present at the Maxim Group Growth Conference on September 29, 2009 at 9:00 a.m. Eastern Time. http://www.pvct.com/pressrelease.html?article=20090916 http://www.pvct.com/pvctnews#0060/ Tue, 1 Sep 2009 13:30:41 +0000 Provectus will present at the Rodman & Renshaw 11th Annual Healthcare Conference in New York City on September 10, 2009. http://www.pvct.com/pressrelease.html?article=20090901 http://www.pvct.com/pvctnews#0059/ Tue, 18 Aug 2009 17:30:34 +0000 Provectus announces that Maxim Group LLC has issued a research report on the Company. http://www.pvct.com/pressrelease.html?article=20090818a http://www.pvct.com/pvctnews#0058/ Tue, 18 Aug 2009 13:41:13 +0000 Provectus has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company's lead dermatology agent PH-10 for psoriasis. http://www.pvct.com/pressrelease.html?article=20090818 http://www.pvct.com/pvctnews#0057/ Tue, 11 Aug 2009 15:42:19 +0000 Provectus reports on its year-to-date clinical and corporate accomplishments in a video and letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. http://www.pvct.com/pressrelease.html?article=20090811 http://www.pvct.com/pvctnews#0056/ Mon, 20 Jul 2009 13:03:11 +0000 Provectus has initiated a new Phase 2 clinical trial of PH-10 for psoriasis involving daily dosing of patients for 28 days. http://www.pvct.com/pressrelease.html?article=20090720 http://www.pvct.com/pvctnews#0055/ Thu, 9 Jul 2009 16:19:14 +0000 The Morning Call published an article entitled "Once a wool dye, chemical could one day be a skin cancer treatment" http://www.mcall.com/news/local/all-a10_5cancer.6945882jul03,0,5571681.story http://www.pvct.com/pvctnews#0054/ Wed, 8 Jul 2009 18:05:42 +0000 Updated Corporate Fact Sheet now available. http://www.pvct.com/FactSheet.pdf http://www.pvct.com/pvctnews#0053/ Wed, 1 Jul 2009 11:10:02 +0000 Provectus has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis. http://www.pvct.com/pressrelease.html?article=20090701 http://www.pvct.com/pvctnews#0052/ Mon, 29 Jun 2009 18:44:07 +0000 Wellspring Health and Fitness posts story on Provectus' compassionate use program for PV-10. http://wellspringhealthandstyle.com/2009/06/26/new-hope-for-cancer-patients/ http://www.pvct.com/pvctnews#0051/ Mon, 22 Jun 2009 15:02:32 +0000 Provectus has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients. http://www.pvct.com/pressrelease.html?article=20090622 http://www.pvct.com/pvctnews#0050/ Fri, 19 Jun 2009 13:28:31 +0000 Provectus held its 2009 Annual Meeting of Shareholders on Thursday, June 18, 2009 in Knoxville, Tennessee. Shareholders voted to re-elect the Company's five members of the Board of Directors, which is composed of three inside directors, and two outside directors. http://www.pvct.com/pressrelease.html?article=20090619 http://www.pvct.com/pvctnews#0049/ Wed, 3 Jun 2009 13:55:21 +0000 St Luke's Hospital news article includes a detailed background and summary of the data presented at ASCO 2009. http://www.mystlukesonline.org/about/news/promising-melanoma-treatment.aspx http://www.pvct.com/pvctnews#0048/ Mon, 1 Jun 2009 12:02:12 +0000 Provectus has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and elicited selective ablation of tumors in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session. http://www.pvct.com/pressrelease.html?article=20090601 http://www.pvct.com/pvctnews#0047/ Mon, 18 May 2009 12:39:14 +0000 Provectus announced that data from its Phase 2 clinical study of PV-10 for metastatic melanoma was presented at the Joint Meeting of the 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology on May 15, 2009 in Vienna, Austria. http://www.pvct.com/pressrelease.html?article=20090518 http://www.pvct.com/pvctnews#0046/ Thu, 14 May 2009 14:42:43 +0000 Provectus has completed patient accrual and initial PV-10 treatment in its Phase 2 trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. http://www.pvct.com/pressrelease.html?article=20090514 http://www.pvct.com/pvctnews#0045/ Wed, 6 May 2009 12:45:32 +0000 Provectus yesterday filed an S-1/A, a post-effective amendment to the SB-2 it filed in early 2008. That filing in 2008 was for the purpose of registering common stock underlying warrants previously issued. http://www.pvct.com/pressrelease.html?article=20090506 http://www.pvct.com/pvctnews#0044/ Tue, 28 Apr 2009 13:56:11 +0000 Provectus announced today that a poster, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)", will be presented on June 1, 2009 in the 8:00 a.m. - 12:00 p.m. General Poster Session (Group F, Brd. F15), at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program at the Orange County Convention Center in Orlando, Florida. Studies V" portion of the program. http://www.pvct.com/pressrelease.html?article=20090428 http://www.pvct.com/pvctnews#0043/ Tue, 21 Apr 2009 13:55:40 +0000 Provectus announced today that the abstract "Chemoablation of metastatic melanoma with intralesional PV-10" has been accepted for oral presentation at the Joint Meeting of the 7th World Congress on Melanoma and the 5th Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria on May 15, 2009, as part of the "Free Communication 26- Clinical Studies V" portion of the program.. http://www.pvct.com/pressrelease.html?article=20090421 http://www.pvct.com/pvctnews#0042/ Wed, 1 Apr 2009 15:57:07 +0000 Updated corporate fact sheet available on the Provectus website. http://www.pvct.com/FactSheet.pdf http://www.pvct.com/pvctnews#0041/ Thu, 12 Mar 2009 13:35:31 +0000 Provectus announced today that interim data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program to be held between May 29 – June 2, 2009 in Orlando, Florida. http://www.pvct.com/pressrelease.html?article=20090312 http://www.pvct.com/pvctnews#0040/ Wed, 11 Mar 2009 13:12:17 +0000 Provectus has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company's lead dermatology agent PH-10 for atopic dermatitis. Jason Emer, M.D. will serve as principal investigator at the new center. http://www.pvct.com/pressrelease.html?article=20090311 http://www.pvct.com/pvctnews#0039/ Wed, 11 Feb 2009 14:59:50 +0000 Professor John F. Thompson, MD will present clinical data on PV-10 at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13, 2009, in New York City. http://www.pvct.com/pressrelease.html?article=20090211 http://www.pvct.com/pvctnews#0038/ Tue, 6 Jan 2009 13:40:07 +0000 Provectus reports on its clinical and corporate accomplishments for 2008 in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. http://www.pvct.com/pressrelease.html?article=20090106 http://www.pvct.com/pvctnews#0037/ Tue, 23 Dec 2008 16:50:40 +0000 has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a seventh major center located at the University of Louisville, in Louisville, KY. Charles Scoggins, M.D. will serve as principal investigator at the new center. http://www.pvct.com/pressrelease.html?article=20081223 http://www.pvct.com/pvctnews#0036/ Thu, 18 Dec 2008 19:28:24 +0000 Provectus has updated the online version of its business presentation to include upcoming dates in 2009. http://www.pvct.com/presskit.html http://www.pvct.com/pvctnews#0035/ Fri, 12 Dec 2008 13:32:41 +0000 A B-roll video package suitable for broadcast news has been produced including footage from the "Perspectives in Melanoma XII" conference held in The Hague in October. http://www.pvct.com/hague_b-roll.html http://www.pvct.com/pvctnews#0034/ Tue, 25 Nov 2008 14:02:17 +0000 Provectus announced today that the first fifty percent (40 of 80) of melanoma subjects have been treated in its Phase 2 clinical trial of PV-10. http://www.pvct.com/pressrelease.html?article=20081125 http://www.pvct.com/pvctnews#0033/ Mon, 24 Nov 2008 18:54:22 +0000 Provectus will present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference in New York on December 2, 2008. http://www.pvct.com/pressrelease.html?article=20081124 http://www.pvct.com/pvctnews#0032/ Mon, 24 Nov 2008 15:14:03 +0000 A paper entitled "Chemoablation of metastatic melanoma using intralesional Rose Bengal" by John F. Thompson, Peter Hersey, and Eric Wachter was published in the December 2008 issue of Melanoma Research. http://www.pvct.com/melanoma-res-200811.html http://www.pvct.com/pvctnews#0031/ Thu, 20 Nov 2008 14:54:31 +0000 Professor John F. Thompson, MD presented an update on clinical testing of PV-10 for metastatic melanoma Wednesday, November 19th, at the Clinical Oncological Society of Australia 2008 Annual Scientific Meeting in Sydney, Australia. Professor Thompson noted that so far 39 of the planned 80 subjects have received at least one course of PV-10 treatment. In addition, long-term survival data for subjects participating in the phase 1 trial were presented. http://www.pvct.com/pressrelease.html?article=20081120 http://www.pvct.com/pvctnews#0030/ Tue, 18 Nov 2008 14:19:33 +0000 The lead investigator for Provectus' Phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Clinical Oncological Society of Australia (COSA) 2008 Annual Scientific Meeting (ASM) in Sydney, Australia. http://www.pvct.com/pressrelease.html?article=20081118 http://www.pvct.com/pvctnews#0029/ Mon, 17 Nov 2008 13:54:12 +0000 has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a sixth major center located at the California Pacific Medical Center, in San Francisco, CA. http://www.pvct.com/pressrelease.html?article=20081117 http://www.pvct.com/pvctnews#0028/ Tue, 4 Nov 2008 13:47:04 +0000 Provectus invited to present at the Rodman & Renshaw 10th Annual Healthcare Conference. http://www.pvct.com/pressrelease.html?article=20081104 http://www.pvct.com/pvctnews#0027/ Tue, 28 Oct 2008 13:52:34 +0000 Provectus announced today that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma. http://www.pvct.com/pressrelease.html?article=20081028 http://www.pvct.com/pvctnews#0026/ Thu, 23 Oct 2008 15:40:33 +0000 In a Next Generation Pharmaceuticals article entitled "The Virtual Company", Provectus CFO Peter Culpepper discusses Provectus' business model with interviewer Willem van Leeuwen, Managing Director of QMR Technology B.V. http://www.ngpharma.com/currentissue/article.asp?art=275461&issue=285 http://www.pvct.com/pvctnews#0025/ Mon, 20 Oct 2008 14:01:47 +0000 Provectus' Chairman and CEO, Craig Dees, Ph.D., will be participating in several investment community events over the next two months. http://www.pvct.com/pressrelease.html?article=20081020 http://www.pvct.com/pvctnews#0024/ Fri, 17 Oct 2008 14:17:20 +0000 Provectus has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a fourth major center, now covering Adelaide, Australia in addition to Sydney and Brisbane, Australia, as well as M.D. Anderson in Houston, Texas, USA. Over the next several months, the Company expects to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States. http://www.pvct.com/pressrelease.html?article=20081017 http://www.pvct.com/pvctnews#0023/ Tue, 14 Oct 2008 17:10:03 +0000 The paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D., is available for purchase at the "Melanoma Research" website. http://www.melanomaresearch.com/pt/re/melres/paptoc.htm http://www.pvct.com/pvctnews#0022/ Tue, 14 Oct 2008 14:32:12 +0000 Provectus announced that "Melanoma Research" has published a paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," on its website. The paper is authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D. The paper details results of Provectus' Phase 1 clinical trial of PV-10, and is scheduled for print publication in the December issue of the journal. http://www.pvct.com/pressrelease.html?article=20081014 http://www.pvct.com/pvctnews#0021/ Mon, 13 Oct 2008 12:30:21 +0000 Provectus CEO Craig Dees, Ph.D., is featured in an exclusive interview on WallSt.Net's 3-Minute Press Show. http://www.pvct.com/pressrelease.html?article=20081013 http://www.pvct.com/pvctnews#0020/ Mon, 6 Oct 2008 14:40:23 +0000 Provectus announced that that the interim safety analysis on the first 20 subjects in its phase 2 clinical trial for the treatment of metastatic melanoma has been completed. PV-10 injection was well tolerated by this group, with an adverse event profile similar to that observed in phase 1. In addition, long-term survival data for subjects participating in the phase 1 trial were presented. http://www.pvct.com/pressrelease.html?article=20081006 http://www.pvct.com/pvctnews#0019/